Children's Hospital Medical Center, Cincinnati: Anemia, Sickle Cell trials

The registry lists 30 Anemia, Sickle Cell studies with Children's Hospital Medical Center, Cincinnati as lead sponsor. 7 are open to participants now and 10 have results posted.

Early Phase 1 1Phase 1 4Phase 2 8Phase 3 3Phase 4 2No phase 15(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Optimizing Hydroxyurea Therapy in Children With Sickle Cell Anemia In Malaria Endemic Areas: The NOHARM Maximum Tolerated Dose (MTD) StudyRecruitingNCT07708714Phase 1/2
• Verifying Antibodies After Live Immunization Delivery (VALID): A Study of Measles Vaccine Immunogenicity in Children With Sickle Cell DiseaseRecruitingNCT07356050
• Effectiveness of Nontraditional Hydroxyurea Algorithms: Novel and Clinical Evaluations (ENHANCE)RecruitingNCT07177300Phase 4
• Serial Assessment of Fertility ExperiencesRecruitingNCT07116772
• Uganda Sickle Surveillance Study (US-3)RecruitingNCT06301893
• A Socio-ecological Approach for Improving Self-management in Adolescents With SCDRecruitingNCT06290401Not applicable
• Hydroxyurea Exposure Limiting Pregnancy and Follow-Up LactationRecruitingNCT04093986
• Shared-Decision Making for HydroxyureaCompletedNCT03442114Not applicableResults posted
• Improving Self-Management in Adolescents With Sickle Cell DiseaseCompletedNCT02851615Not applicableResults posted
• Novel Cardiac Magnetic Resonance Imaging to Define a Unique Restrictive Cardiomyopathy in Sickle Cell DiseaseCompletedNCT02410811Results posted
• Patient-Provider Tools to Improve the Transition to Adult Care in Sickle Cell DiseaseCompletedNCT02200510Not applicableResults posted
• Realizing Effectiveness Across Continents With Hydroxyurea (REACH)Active, not recruitingNCT01966731Phase 1/2Results posted
• Sparing Conversion to Abnormal TCD (Transcranial Doppler) Elevation (SCATE)TerminatedNCT01531387Phase 3Results posted
• Losartan to Reverse Sickle NephropathyCompletedNCT01479439Phase 2Results posted
• Transcranial Doppler (TCD) With Transfusions Changing to HydroxyureaTerminatedNCT01425307Phase 3Results posted
• Dexamethasone to Treat Acute Chest Syndrome in People With Sickle Cell DiseaseTerminatedNCT00530270Phase 3Results posted
• Ketorolac Versus Ibuprofen to Treat Painful Episodes of Sickle Cell DiseaseTerminatedNCT00115336Phase 4Results posted
• Full Assessment of Clinical Transfusion SupportCompletedNCT07094646
• Realizing Effectiveness Across Continents With HydroxyureaActive, not recruitingNCT06171217Phase 2
• Alternative Dosing And Prevention of Transfusions (ADAPT)Active, not recruitingNCT05662098Early Phase 1
• Losartan for Diffuse Myocardial Fibrosis in Sickle Cell DiseaseCompletedNCT05012631Phase 2
• Hydoxyurea Exposure in Lactation A Pharmacokinetics Study (HELPS)CompletedNCT02990598
• SACRED A Prospective Research Study to Reduce Stroke in Children With Sickle Cell AnemiaCompletedNCT02769845Not applicable
• EXTEND EXpanding Treatment for Existing Neurological DiseaseCompletedNCT02556099Phase 2
• Therapeutic Response Evaluation and Adherence Trial (TREAT)Active, not recruitingNCT02286154Not applicable
• Screening Patients With Sickle Cell Disease for Kidney DamageCompletedNCT02239016
• Gene Transfer for Patients With Sickle Cell DiseaseTerminatedNCT02186418Phase 1/2
• Trial of Zileuton CR in Children and Adults With Sickle Cell DiseaseCompletedNCT01136941Phase 1
• Role of Placenta Growth Factor in Sickle Acute Chest SyndromeCompletedNCT00448370
• Dipyridamole/Magnesium To Improve Sickle Cell HydrationWithdrawnNCT00276146Phase 2